Cephalexin Chewable Tablets

Verify with FDA CVM →

19 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
3
Deaths Reported
1580.0%
Death Rate

Active Ingredients

Cephalexin Chewable Tablets

Administration Routes

UnknownOral

Species Affected

Dog 19

Most Affected Breeds

Retriever - Labrador 2
Shepherd Dog - German 2
Boxer (German Boxer) 2
Pinscher - Miniature 2
Crossbred Canine/dog 1
Terrier (unspecified) 1
Lhasa Apso 1
Chow Chow 1
Terrier - Silky 1
Bichon Frise 1

Most Reported Reactions

Vomiting 5
Other abnormal test result NOS 4
Elevated alanine aminotransferase (ALT) 3
Death 3
Anorexia 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Neutrophilia 2
Elevated serum alkaline phosphatase (SAP) 2
Bradycardia 2
Thrombocytopenia 2
Leucocytosis NOS 2
Abdominal discomfort 2

Outcome Breakdown

Ongoing
12 (63.2%)
Died
3 (15.8%)
Recovered/Normal
2 (10.5%)
Outcome Unknown
2 (10.5%)

Data Summary

Metric Value
Total adverse event reports 19
Reports involving death 3
Case-fatality rate (reported events) 1580.0%
Distinct species in reports 1
Distinct breeds in reports 15
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Cephalexin Chewable Tablets Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 19 adverse event reports referencing Cephalexin Chewable Tablets, including 3 reports in which the animal died — a 1580.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Cephalexin Chewable Tablets. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Cephalexin Chewable Tablets reports are Dog (19 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (2), Shepherd Dog - German (2), Boxer (German Boxer) (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Cephalexin Chewable Tablets are Vomiting (5), Other abnormal test result NOS (4), Elevated alanine aminotransferase (ALT) (3), Death (3). Of the 19 reports with a coded outcome, Ongoing is the leading category at 63.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Cephalexin Chewable Tablets.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial